Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 426 of 5804
-
Sound waves aimed at the brain could quiet seizures
Disease control Recruiting nowThe goal of this study is to investigate the effects of a non-invasive, low intensity focused ultrasound (LIFU) stimulation on seizure frequency and the epileptogenic network in drug-resistant epilepsy. LIFU uses focused sound waves to modulate deep brain regions and to enable ch…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental drug GLM101 targets rare PMM2-CDG in pivotal trial
Disease control OngoingThis study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults. Researchers will compare participants receiving GLM101 to those receiving a placebo to se…
Phase: PHASE2, PHASE3 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThe purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
Phase: PHASE3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Recruiting nowA Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma.
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Head-to-Head: which migraine pill works best?
Disease control Recruiting nowThis goal of this study is to compare three medications used for migraine preventive treatment. This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better…
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a drug combo replace chemo and transplant for multiple myeloma?
Disease control Recruiting nowThis study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT. 824 patients will be enrolled in this study from approximately 70 study sites. The 2 parts in the Treat…
Phase: PHASE3 • Sponsor: Intergroupe Francophone du Myelome • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
BREAST CANCER BREAKTHROUGH? new study lets patients choose chemo-free treatment
Disease control Recruiting nowThis is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or premenopausal women T2-3N0 and RS 16-25, or T1-3N1-2 and RS ≤ 25, and postmenopausa…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental drug aims to shield ICU patients from deadly infections
Disease control Recruiting nowThe goal of this clinical trial is to demonstrate the benefit of a standardized immunotherapy (Interferon gamma) on the incidence of secondary infections. . It will also learn about the safety of Interferon-gamma. The main questions it aims to answer are: Does Interferon-gamma: …
Phase: PHASE3 • Sponsor: University Hospital, Limoges • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could this vaccine stop future coronavirus pandemics?
⭐️ VACCINE ⭐️ OngoingCoronaviruses (CoVs) have caused the severe acute respiratory syndrome (SARS) outbreak, the Middle East Respiratory Syndrome (MERS) outbreak, and now the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although there are several approved or authorized vacci…
Phase: PHASE1 • Sponsor: Duke University • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:06 UTC
-
New vaccine targets rare liver cancer's genetic flaw
⭐️ VACCINE ⭐️ Recruiting nowThe aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusio…
Phase: PHASE1 • Sponsor: University Hospital Tuebingen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThe study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for High-Risk prostate cancer: which targeted radiation works best?
Disease control Recruiting nowThere is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in t…
Phase: PHASE1 • Sponsor: Thomas Hope • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New vaccine against rift valley fever shows promise in early trial
⭐️ VACCINE ⭐️ OngoingThe goal of this clinical trial is to learn if ChAdOx1 RVF, a candidate vaccine against RVF, provides an adequate immune response and determine its safety among Kenyan adults. The main aims are: * To assess the proportion of individuals mounting an immune response following vacc…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:57 UTC
-
Lung cancer hope: new combo aims to stop tumor growth
Disease control Recruiting nowThis is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled. The treatment is Atezolizumab + Paclitaxel + Carboplatin 3 cycles as neoadjuvant/induction treatment. After the induction treatment eve…
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowBackground: Mesothelioma is an aggressive cancer that grows in the linings of the body; this can include the membranes that line the heart, lungs, and internal organs. Mesothelin (MSLN) is a protein that appears in high numbers in many tumors, including mesothelioma. Researchers…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Recruiting nowThe goal of this clinical trial is to test the feasibility and safety of an academic production of two different anti-CD19 chimeric antigen receptor T cells (CART) products according to the different biomarkers of the disease in children and young adults with relapsed/refractory …
Phase: PHASE1 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New COVID-19 vaccine trial targets High-Risk groups
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19. This study is seeking participants 12 through 64 years of age who are considered to be at higher risk for severe COVID-19 disease per study protocol a…
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
Gene therapy eye drops aim to heal corneas in rare nerve disorder
Disease control Recruiting nowThe Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via top…
Phase: PHASE1, PHASE2 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Booster shot study aims to keep teens safe from meningitis b
⭐️ VACCINE ⭐️ CompletedThe main purpose of this study is to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focuses on individuals who were first vaccina…
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to tackle Hard-to-Treat lung cancer
Disease control Recruiting nowThis study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet chemotherapy compared with platinum-based doublet chemotherapy…
Phase: PHASE3 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC